ERBB2 and non-small cell lung carcinoma: Additionally, the ongoing phase Ib DESTINY-Lung03 trial (NCT04686305) is evaluating the safety, tolerability, and efficacy of T-DXd in combination with Durvalumab and chemotherapy as a first-line treatment in advanced HER2-overexpressed NSCLC (109).